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Abstract
We describe the development of a versatile fluorescence resonance energy transfer (FRET)-based 
real-time monitoring system, consisting of (a) coumarin-labeled-cysteine tethered mesoporous 
silica nanoparticles (MSNs) as the drug carrier, (b) a fluorescein isothiocyanate-β-cyclodextrin 
(FITC-β-CD) as redox-responsive molecular valve blocking the pores, and (c) a FRET donor-
acceptor pair of coumarin and FITC integrated within the pore-unlocking event, thereby allowing 
for monitoring the release of drugs from the pores in real-time. Under non-reducing conditions, 
when the disulfide bond is intact, the close proximity between coumarin and FITC on the surface 
of MSNs results in FRET from coumarin to FITC. However, in the presence of the redox stimuli 
like glutathione (GSH), the disulfide bond is cleaved which leads to the removal of molecular 
valve (FITC-β-CD), thus triggering drug release and eliminating FRET. By engineering such a 
FRET-active donor-acceptor structure within the redox-responsive molecular valve, we can 
monitor the release of the drugs entrapped within the pores of the MSN nanocarrier, following the 
change in the FRET signal. We have demonstrated that, any exogenous or endogenous change in 
the GSH concentration will result in a change in the extent of drug release as well as a concurrent 
change in the FRET signal, allowing us to extend the applications of our FRET-based MSNs for 
monitoring the release of any type of drug molecule in real-time.
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It has been known that diseased/injured microenvironments release different biological cues 
and follow abnormal regulatory cycles, when compared to physiologically normal cells and 
tissues.1–3 Such dynamic microenvironmental conditions require scientists to develop more 
effective nanomaterial-based drug delivery systems (DDSs) having the following attributes: 
i) they can deliver multiple drugs such as organic small molecules, proteins, peptides, DNA, 
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and RNAi molecules without any physicochemical alterations to drug structure,4–8 ii) they 
can modulate the drug-release profile in response to external or internal stimuli for 
enhancing therapeutic efficacy and minimizing side-effects of drug treatment,9–15 and iii) 
they can monitor the drug release in real time for investigating accumulation of the drugs at 
the targeted area.16–21 In this regard, mesoporous silica nanoparticles (MSNs) have excellent 
potential as DDSs owing to their unique porous structure, tunable pore size, 
biocompatibility, ease of surface functionalization, and overall versatility.22–24 The 
hexagonal-ordered pore network within these MSNs allows for entrapping drugs within 
these pores by simple diffusion. Additionally, the pores can be functionalized with 
molecular valves designed to trigger the release of the entrapped drugs in the presence of 
external or internal stimuli including light,25–29 temperature,30–32 pH,33–37 and 
biomolecules.38–42 While there have been numerous reports on the design and development 
of stimuli-responsive MSNs for drug delivery, development of strategies for real-time 
monitoring of drug release inside the targeted cells is still in its nascent stage. The most 
widely used amongst these strategies include using fluorescent dyes/drugs as a model cargo 
system,18–35 or conjugating the drugs with caged dyes.19, 20 However, such strategies come 
with their own limitations such as difficulty in correlating the release of the fluorescent 
model dye to that of the actual drug molecules; restricting the usage of fluorescent drugs like 
doxorubicin as model cargoes, although most of the current drug candidates are non-
fluorescent; and possibility of affecting the therapeutic efficacy of the drug owing to 
structural changes required for conjugation of dyes. Such challenges in investigating the 
release of drug in complex cellular microenvironments necessitate the development and 
integration of a real-time monitoring system within the stimuli-responsive nanomaterial-
based DDSs.
To address the aforementioned issues, herein we describe the synthesis and development of 
a redox-responsive fluorescent resonance energy transfer based MSN drug delivery system 
(henceforth referred to as FRET-MSN), which enables real-time monitoring (based upon the 
FRET signal) of redox-responsive drug release occurring in the presence of glutathione 
found in significantly higher levels in the cancer cells (Figure 1).43–45 Fluorescence 
resonance energy transfer (or Förster resonance energy transfer, FRET) is a well-established 
energy transfer process between two fluorophores which is very sensitive to changes at 
nanometer-scale (typically less than 10 nm) in the donor-to-acceptor separation distance.46 
This unique feature of FRET can potentially be an ideal tool to monitor delicate interactions 
between nanomaterial-based DDSs and external/internal stimuli.47, 48 As illustrated in 
Figure 1, our FRET-based real-time monitoring platform is comprised of four components: 
(i) coumarin (donor)-tethered MSNs as the drug carriers, (ii) fluorescein isothiocyanate 
(FITC, acceptor)-attached β-cyclodextrin (β-CD) as the molecular cap to entrap the drugs 
within the MSNs, (iii) disulfide linkage as the redox-responsive trigger to release the 
entrapped drug molecules, and (iv) FRET donor-acceptor pair of coumarin and FITC for 
monitoring drug release in real time. Under non-reducing conditions (e.g. without 
glutathione),49 the intact disulfide bond supports formation of a donor-acceptor complex 
between the coumarin-attached MSN and the FITC-β-CD molecular cap, thereby creating a 
FRET system. At this stage (FRET ON), the coumarin and FITC moieties are in close 
proximity on the MSN surface and the FRET-MSNs display an emission peak at 520 nm 
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(correlated to energy transfer from coumarin to FITC), when they are excited at 405 nm (the 
excitation wavelength of coumarin). However, in the presence of a reducing environment 
(e.g. with glutathione), the disulfide bond can be cleaved,49 causing the removal of the 
FITC-β-CD cap from the MSNs, thereby unlocking the pores and releasing the cargo within. 
Upon cleavage of the disulfide bond, the FITC-β-CD diffuses away from the MSN surface, 
hence the FRET between coumarin and FITC is abolished (FRET OFF), and the MSNs 
display emission at 450 nm (characteristic of coumarin) when excited at 405 nm. Since the 
on/off change in FRET signal is regulated by molecular structures within our platform and 
correlated to the unlocking event, we can monitor and quantify the drug release process, by 
measuring the change of FRET signal. By monitoring the FRET signal on the nanoparticles 
in real-time, we can visualize the release of any drug molecules, without relying on the 
drug’s optical properties, thereby extending the application of our FRET-MSNs to many 
drug molecules without compromising their efficacy.
RESULTS AND DISCUSSION
Synthesis and Characterization of FRET-MSNs
The generation of our FRET-MSN-based drug delivery system began with the synthesis of 
MCM-41type MSNs via condensation of tetraethylorthosilicate (TEOS) in the presence of a 
cetyltrimethylammonium bromide (CTAB) micelle template (Figure 2A).50 These MSNs 
were then functionalized with 3-aminopropyltriethoxysilane (APTES) and grafted with N-
Boc-cysteine via an amide bond. The thiol group of cysteine was conjugated with 1-
adamantanethiol to form an redox-responsive disulfide bond, while the amine group was 
further labeled with 3-carboxy-7-hydroxyl-coumarin (CHC) to obtain the functional CHC-
MSNs. Using transmission electron microscopy (TEM), we affirmed that the CHC-MSNs 
still retain the characteristics of MCM-41 type of MSNs, such as their spherical particle 
shape, having an average diameter of 100 nm ± 14 nm (n = 100) and hexagonally packed 
mesoporous structures (Figure 2B). This was also substantiated by N2 adsorption isotherms 
which demonstrated that the CHC-MSNs have a Burnauer-Emmett-Teller (BET)-surface 
area of 398 m2·g−1 and a narrow Barrett-Joyner-Halenda (BJH) pore-size distribution 
(average pore diameter = 2.3 nm) (see Supporting Information, Figure S2). In addition, the 
cysteine functionalized MSNs show a characteristic Raman peak of free thiol group51 at 
2550 cm−1 (Figure 2C, top curve). However, after conjugation with 1-adamantanethiol via a 
disulfide bond, this characteristic free thiol peak disappeared, which confirmed the 
formation of a disulfide bond (Figure 2C bottom curve). Figure 2D shows the UV-Vis 
absorption and fluorescence emission of CHC-MSNs, demonstrating the successful 
conjugation of CHC to the MSN surface and indicates that the CHC-moiety can act as the 
energy donor for FITC (see Supporting Information, Figure S4). Together with the FTIR 
characterization of CHC-MSNs (see Supporting Information, Figure S3), these results 
demonstrated the successful construction of CHC-MSNs.
Assembly of a Donor-Acceptor FRET Model
The synthesis of FRET-MSNs was then followed by the combination of the CHC-MSNs 
with FITC-β-CD via host-guest complexation between FITC-β-CD and adamantane 
moiety52 present on CHC-MSNs (Figure 3A). As shown in Figure 2D, the coumarin moiety 
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in CHC-MSNs can be excited by absorbing light with a wavelength of 405 nm, resulting in 
emission of light in the range of 430–480 nm. When the disulfide bond is intact (Figure 1), 
the coumarin moiety in CHC-MSNs upon excitation at 405 nm will act as a photon donor 
for the FITC-β-CD which absorbs maximally at 480 nm (see Supporting Information, Figure 
S4). We observed that the addition of FITC-β-CD lead to a decrease in blue fluorescence 
(450 nm) and an increase in green fluorescence (520 nm) (Figure 3B), which was also 
reflected in a significant change of the color of the solution from blue to green, sufficiently 
distinct to be identified via naked eye (Figure 3A, inset). As seen in Figure 3B, further 
increases in the concentration of FITC-β-CD quenched the blue fluorescence maximally. 
Additionally, from the data shown in Figure 3B, the ratio of relative fluorescence intensities 
(FRET signal R, where R = F520nm / F450nm) reached a value of 1.25 at a concentration of 3 
µM for FITC-β-CD for a fixed concentration of CHC MSNs (10 µg·mL−1), which indicated 
the assembly of FITC-β-CD to the MSN surface reached a saturation point. Further addition 
of FITC-β-CD beyond the saturation point only led to an increase in the FITC fluorescence 
with negligible quenching of coumarin fluorescence, presumably due to the direct excitation 
of FITC at 405 nm.46 When these nanoparticles were isolated from the solution and 
redispersed in PBS (pH 7.4), they displayed dual emission peaks at 450 nm and 520 nm 
upon excitation at 405 nm (see Supporting Information, Figure S5a). Collectively, these 
results demonstrated that FITC-β-CD can assemble onto the surface of the CHC-MSN 
surface through the formation of inclusion complex with 1-adamantanethiol, thereby 
inducing a donor-acceptor FRET system.
Redox-Responsive Behavior of FRET-MSNs
The redox-responsive property of the FRET-MSNs was examined by observing the changes 
in FRET signal in the presence of glutathione (GSH) which mimics the intracellular 
reducing environment (Figure 3A). As shown in Figure 3C, addition of increasing 
concentrations of GSH (0.1 – 5 mM) to a buffered solution of FRET-MSNs induced a 
decrease in the green fluorescence (520 nm) accompanied by recovery of blue fluorescence 
(450 nm) upon excitation at 405 nm. This strongly indicated the cleavage of disulfide bond 
and the removal of the FRET acceptor, FITC-β-CD. Accordingly, the color of the solution 
changed from green to blue under UV lamp (365 nm) (Figure 3A, inset). Fluorescence 
spectrum of the isolated nanoparticles after redispersing in PBS (pH 7.4) revealed that these 
nanoparticles only show the emission at 450 nm (see Supporting Information, Figure S5b). 
Based on these results, we can confirm the redox-responsive behavior of our FRET-MSNs, 
which results in a concomitant change in the FRET signal.
Correlating Drug Release from FRET-MSNs to the FRET Signal
Once we confirmed the redox-responsive gating behavior of our FRET-MSNs, our next step 
was to utilize their FRET properties for monitoring the drug release from the pores. Since 
the modulation of FRET is integrated within the uncapping event, we hypothesize that the 
corresponding change in the FRET signal can be utilized for monitoring the drug release on 
a temporal level (Figure 4A). To demonstrate this, we chose doxorubicin (DOX) as our 
model cargo, which was loaded into the pores of MSNs by first mixing aqueous buffered 
solutions of CHC-MSNs and DOX for 12 h. Thereafter, the pores were capped with FITC-β-
CD and the final product (DOX-loaded FRET-MSNs) was isolated by centrifugation after 
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repeated washing. The amount of DOX loaded into the pores of FRET-MSNs was 
determined to be 41.3 mg DOX/g of FRET-MSNs. It should be noted that the DOX-loaded 
FRET-MSNs were well-dispersed in aqueous solutions, owing to the presence of 
hydrophilic β-CD moieties on their surface, which can be exploited for the delivery of 
hydrophobic cargoes, like anti-cancer drugs.53 To investigate the capping efficiency, DOX-
loaded FRET-MSNs were dispersed in PBS (pH 7.4) and the absorbance of the released 
DOX in the absence of GSH was first monitored. As shown in Figure 4B (curve a), 
negligible release of DOX was observed over a period of 24 h, indicating that the FRET-
MSNs remain intact in the absence of GSH. In contrast, the release profiles of DOX in the 
presence of varying concentrations of GSH depict an increase in the percent DOX released 
as time progressed (Figure 4B, curve b–d). From Figure 4B, we can see that the percent 
DOX released from the FRET-MSNs was dependent on GSH concentration, wherein 
concentrations of 0.1 mM or higher lead to significantly faster and greater release of DOX. 
Since the release of DOX only occurs when the pores are unlocked as a consequence of 
FITC-β-CD diffusing away from the FRET-MSNs, we also observed a corresponding 
change in the FRET signal R. As shown in Figure 4C, addition of GSH (0.1 mM) to Dox-
loaded FRET-MSNs induced a relatively slow time-dependent decrease in FRET signal over 
a period of 3 h, while higher concentrations of GSH lead to faster decrease in the FRET 
signal, reaching a minimal value of R within 1 h at 5 mM concentration of GSH. These 
GSH-concentration induced changes in FRET signal remained constant over a period of 24 
h, at which the release of DOX also reached a plateau. From this data (t = 24 h), a 
correlation between the amount of DOX released and FRET signal R was obtained (Figure 
4D), which strongly suggested that the FRET-MSNs have the capability of monitoring the 
drug release in real-time.
Observing FRET Change in Cancer Cells Using FRET-MSNs
Prior to using the FRET-MSNs for cellular studies, we identified a range of concentrations 
within which the FRET-MSNs demonstrated minimal cytotoxicity (see Supporting 
Information, Figure S6). Using a cell proliferation assay, we found that concentrations lower 
than 20 µg·mL−1 induced negligible cytotoxicity in HeLa cells and hence for all of our 
experiments, we utilized FRET-MSNs within this concentration range. To investigate the 
change in FRET signal following uptake and localization of FRET-MSNs in mammalian 
cells, we incubated the FRET-MSNs with cervical cancer cells (HeLa) and observed the 
change in FRET signal over extended periods of time (0 to 24 h) using confocal 
fluorescence microscopy. As seen in Figure 5A (top left), at time t = 0 h, blue-green spots 
were visible in the perinuclear region of HeLa cells when they were excited using 405 nm 
light, indicating intact FRET-MSNs with the FRET signal ON. From the emission spectrum 
(Figure 5A, top right), we can see that these spots show lower blue emission, but stronger 
green emission thus confirming that most of the FRET-MSNs were in the "FRET ON" stage 
at this time-point. However, at approximately t = 24 h, an increase in the blue fluorescence 
intensity and a corresponding decrease in the green fluorescence intensity (Figure 5A, 
bottom left) were observed when the cells were excited using 405 nm light. This was 
consistent with our expectation as the cleavage of disulfide bond would lead to the removal 
of FITC-β-CD cap, thereby leading to the recovery of the blue fluorescence intensity (Figure 
5A, bottom right). The removal of FITC-β-CD cap was further confirmed by observing 
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diffuse FITC fluorescence throughout the cytoplasm, when the cells were excited using 
FITC channel (488 nm) (see Supporting Information, Figure S8). These results demonstrated 
that we were able to monitor the change in the intracellular FRET signal over a period of 
time by using confocal microscopy.
As shown earlier, we have already demonstrated that our FRET-MSNs can respond to the 
presence of exogenous GSH by releasing the entrapped cargo with concurrent change in the 
FRET signal. However, in order to demonstrate this in mammalian cells, we used thioctic 
acid (TA, a GSH synthesis enhancer, 10 µM)54 and N-ethylmaleimide (NEM, a GSH 
scavenger, 5 µM)55, 56 to modulate the intracellular GSH concentration. The HeLa cells 
were incubated with TA and NEM, 10 min prior to incubating with the FRET-MSNs and 
were subsequently analyzed using fluorescence microscopy. As depicted in Figure 5B, we 
observed a clear enhancement in the characteristic coumarin emission at 450 nm for the cells 
treated with TA in FRET channel (Ex = 405 nm), coupled with increased FITC fluorescence 
in FITC channel (Ex = 488 nm), indicating that higher number of the molecular valves 
(FITC-β-CD) were being removed from the surface of FRET-MSNs due to increased 
intracellular GSH concentration and were subsequently diffused into the cytoplasm. On the 
contrary, a distinct punctate blue-green fluorescence in FRET channel, indicating FRET ON, 
was seen in the perinuclear region in case of cells treated with NEM. Since NEM decreases 
intracellular GSH concentration, there will be negligible cleavage and subsequent release of 
FITC-β-CD, hence resulting in the FRET being ON. As seen in Figure 5C, quantitative 
analysis of the relative intensities of coumarin emission (Ex = 405 nm. Em = 450 nm) also 
showed a similar trend of increasing coumarin emission as the intracellular GSH 
concentration increased. Based on these results, we were also able to confirm that the release 
of the molecular gate (FITC-β-CD) occurred in response to the redox stimuli, GSH present 
in millimolar levels in the cytoplasm of cancer cells.43–45
Monitoring Drug Release in Real-time in Cancer Cells Using FRET-MSNs
However, it is important to demonstrate if we can correlate this change in the FRET signal 
with the corresponding drug release and its downstream therapeutic efficacy. To prove this, 
we treated HeLa cells with TA and NEM to modulate the cytoplasmic GSH concentration 
prior to the addition of DOX-loaded FRET-MSNs, and the viability of HeLa cells was 
monitored 24 h after treatment. The change in intracellular GSH concentration will result in 
a change in the extent of disulfide bond cleavage, which shall be displayed as a change in 
the FRET signal R as well as the amount of DOX released. Since the amount of DOX 
released from the nanoparticles influences the viability of cells, we can then correlate the 
change in FRET signal with the cell viability. As expected, the presence of TA, which 
increased the intracellular GSH concentration, led to an increase in the unlocking of pores 
which was associated with a decrease in the cell viability as well as an decrease in the FRET 
signal, R (thus 1/R increases as seen in Figure 5D, FRET OFF). In contrast, when the cells 
were pre-treated with the GSH scavenger, NEM, we observed an increase in the cell 
viability as well as a increase in the FRET signal ratio, R (thus 1/R decreases as seen in 
Figure 5D, FRET ON). These results demonstrated the ability of our proposed FRET-MSNs 
based DDS in real-time monitoring drug release and reporting cell viability.
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In summary, we have successfully demonstrated the formation of redox-responsive 
fluorescent MSNs, comprised of an integrated FRET-based real-time monitoring system, 
which enabled tracking the release of the payload from the pores of the MSNs in real-time, 
by measuring the change in the FRET signal. We have shown a good correlation between 
the change in the FRET signal and the extent of drug released at different GSH 
concentrations both at the solution level as well as inside the cells. The advantage of our 
platform is that it can be extended to any cargo, fluorescent or non-fluorescent, as the 
molecular structures responsible for real-time monitoring are integrated within the unlocking 
mechanism present on the nanoparticle, and hence, we do not need to rely on the optical 
properties of the drug or a model dye. As such, we can monitor the release of the cargo on a 
temporal level, even if the drug is non-fluorescent, thus demonstrating the versatility of our 
platform. Additionally, no structural modification of the drug is required as the donor-
acceptor pair is integrated within the nanoparticles, thereby preserving the drug efficacy. 
Numerous studies have demonstrated significantly higher intracellular glutathione 
concentrations in cancer cells as compared to normal cells, we can expect our FRET-MSNs 
to release the biomolecules more selectively in cancer cells. However, we can expect to 
extend the applications of the FRET-MSNs to any trigger such as pH or temperature by 
making appropriate structural modifications, since the FRET signal only depends on the 
donor-acceptor pair. Thus, we can envision our real-time monitoring system would provide 
a unique and universal strategy for overcoming the challenges encountered in the tracking 
(location) and monitoring (time) of drug release over extended periods of time and shows 
great potential for bio-applications, such as the investigation of cancer stem cells and 
effective therapies against them. However, a more advanced real-time monitoring system 
should also possess the capability of achieving direct monitoring of the release kinetics of 
drugs. Hence, we will explore additional avenues for enabling our FRET-MSNs to precisely 
monitor the kinetics of drug release as our future goals.
METHODS
Synthesis of FRET-MSNs
(a) NH2-MSNs.50 In a typical synthesis procedure, 28 mg of sodium hydroxide and 100 mg 
of cetyl trimethyammonium bromide (CTAB) in sequence were completely dissolved into 
50 mL of deionized water under vigorous stirring at 80 °C. After the solution became clear, 
0.5 mL of TEOS was added dropwise in 10 min. After 3 hours, 20 µL of APTES was added 
and the vigorous stirring was continued for 20 h, and then milk-white as-synthesized 
materials were collected by centrifugation. In order to remove the surfactant, the as-
synthesized materials were refluxed in a solution consisting of 50 mL ethanol and 0.5 mL 
hydrochloric acid (36–38%) for 12 hours, centrifuged and finally washed several times with 
methanol. The final products were dried for 12 h at 120 °C in vacuum.
(b) Cys-MSNs. To a solution of N-Boc-cysteine (22 mg) and N-hydroxysuccinimide (NHS, 
25 mg) in 5 mL anhydrous DMF at 0 °C, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC·HCl, 31 mg) was added. The solution was stirred at 0 °C for 30 min 
and recovered to room temperature for additional 4 hours. Then 100 mg of NH2-MSNs in 5 
Lai et al. Page 7













mL DMF solution was added slowly and the mixture was keep stirring overnight under N2. 
The nanoparticles were collected by centrifugation and washed several times with DMF and 
methanol, and finally dried in vacuum to obtain Cys-MSNs.
(c) Cys-TA-MSNs. A solution of Cys-MSNs (80 mg) in 5 mL methanol was added 
dropwise into a solution of 2,2’-dithiodipyridine (0.1 g) in methanol/pH7.4 PBS solution 
(v/v, 10 mL/1.5 mL). The mixture was stirred at room temperature overnight and the 
nanoparticles were collected by centrifugation, washed thrice with methanol and finally 
redispersed in 10 mL methanol. 1-adamantanethiol (0.1 g) in 2 mL methanol was then added 
to the above solution and the mixture was stirred overnight at room temperature under N2 
atmosphere. The Cys-TA-MSNs were collected by centrifugation, washed several times 
with methanol, and then dried under vacuum.
(d) CHC-MSNs. 5 mL DCM solution of Cys-TA-MSNs (60 mg) was cooled to 0 °C for 30 
min and then 2 mL trifluoroacetic acid (TFA) were added. The mixture was stirred at 0 °C 
for 30 min and then recovered to room temperature for an additional 3 hours. Then 10 mL of 
methanol was added to dilute the mixture. The nanoparticles were collected by 
centrifugation and washed several times with methanol, dried in vacuum, and finally 
redispersed in 5 mL anhydrous DMF. To a solution of 7-hydroxycoumarin-3-carboxylic acid 
(100 mg) and NHS (80 mg) in 5 mL anhydrous DMF at 0 °C, 70 mg of EDC·HCl were 
added. The solution was stirred at 0 °C for 30 min and recovered to room temperature for an 
additional 4 hours. Then, the 5 mL of DMF solution consisting of TFA-treated Cys-TA-
MSN nanoparticles was added slowly to the solution and the mixture was keep for stirring 
overnight. The nanoparticles were collected by centrifugation and washed several times with 
DMF and methanol, and then finally dried in vacuum to obtain the CHC-MSNs.
Synthesis of FITC-β-CD—Mono-6-deoxy-6-amino-β-cyclodextrin (NH2-β-CD) was first 
synthesized by a previously reported method.57 1H NMR (300 MHz, D2O): δ 4.97 (s, 7H), 
3.74–3.88 (m), 3.38–3.56 (m), 3.08 (d, 1H, J = 14.2 Hz), 2.84 (dd, 1H, J1 = 7.0 Hz, J2 = 
14.1 Hz). ESI-MS m/z 1132.3 [M-H]−. 38 mg FITC, 10 mg DMAP and 0.1 g NH2-β-CD 
were added into 5 mL anhydrous DMF and the solution was stirred overnight at room 
temperature under N2. 10 mL acetone was added to the solution and the precipitate was 
collected and washed with acetone several times. ESI-MS m/z 1521.9 [M-H]−, 761.3 
[M-2H]/2−.
Characterizations—UV-vis absorption spectra were recorded on a Varian Cary 50 
spectrophotometer. Fluorescence spectra were recorded on a Varian Cary Eclipse 
fluorescence spectrophotometer. FT-IR spectra were collected on an Avatar Nicolet FT-
IR330 spectrometer. Raman spectrum characterizations were performed on Laser Raman, 
Renishaw inVia Raman microscope. 1H NMR was acquired on Varian 300MHz NMR 
spectrometer. ESI-MS was collected on Finnigan LCQ™ DUO LC/MS spectrometer. 
Transmission electron microscopy (TEM) was performed on a Topcon 002B electron 
microscope at 200 kV. Sample preparation was carried out by placing a drop of the freshly 
prepared colloidal solution on a carbon-coated copper grid and allowing the solution to 
evaporate. Nitrogen adsorption-desorption measurements were performed on a 
Micromeritics Tristar-3000 surface area analyzer at −196°C. The sample was dried at 200°C 
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for 3 h before analysis. The Burnauer-Emmett-Teller (BET) specific surface areas were 
calculated using the first 10 experimental data points. Pore volumes were determined from 
the amount of N2 adsorbed at the single point, P/P0 = 0.98.
Cell-lines and culture—HeLa cells were used for FRET-MSNs. HeLa cells were 
cultured in DMEM supplemented with 10% FBS and 1% streptomycin-penicillin. For the 
delivery experiment, passaged cells were prepared to 40–60% confluency in 24-well plates. 
After 24 h of plating, media was exchanged with serum-free basal media (500 µL) and 
FRET-MSNs/ X-tremeGENE complexes (50 µL) were added. After incubation for 6 hours, 
media was exchanged with normal growth medium. Fluorescence measurements were 
performed after 0–24 h after transfection.
Imaging of FRET-MSNs—At different time points following transfection, the cells were 
imaged using fluorescent microscopy. The effect of GSH concentration on the FRET signal 
was studied using the eplifluorescence microscopy. For this purpose, the fluorescent and 
phase contrast images were obtained using the Nikon T2500 inverted epifluorescence 
microscope. Each image was captured with different channels and focus. Images were 
processed and overlapped using Image-Pro (Media Cybernetics) and ImageJ (NIH). In order 
to monitor and quantify the change in FRET signal in vitro, confocal imaging was done 
using Zeiss LSM 510-META confocal microscope equipped with an Axiovert 200 inverted 
Scope.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Schematic representation of the redox responsive FRET-MSNs. (A) The coumarin-labeled 
cysteine on the surface of the FRET-MSNs act as a donor and the FITC-β-CD act as an 
acceptor, thereby forming a FRET system when the disulfide bond is intact (left). When 
disulfide bond is cleaved in the presence of redox stimuli, glutathione, the FITC-β-CD, 
which also acts as the molecular valve, is removed from the surface of the MSNs, thereby 
the FRET between coumarin and FITC is abolished. (B) The delivery of encapsulated cargo 
is selectively triggered in the presence of the redox-stimuli, glutathione which is found in 
significantly higher amounts in the cytoplasm of cancer cells and the concomitant change of 
FRET signal can be used to report the uncaging event and estimate the dosing amount of 
drug. Figure 1A is a magnified representation of Figure 1B, indicating the FRET system.
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(A) Schematic illustration of the synthesis of CHC-labeled MSNs. The CHC moiety acts as 
the FRET donor in our FRET-MSNs. (B) TEM image of CHC-MSNs. Scale bar is 50 nm. 
TEM image confirms that CHC-MSNs retain characteristics typical of MCM-41 type 
nanoparticles. (C) Raman spectra confirming the formation of a disulfide bond, following 
conjugation with 1-adamantane thiol. The top curve indicates the free thiol (-SH) moiety on 
the surface of CHC MSNs, prior to conjugation with 1-adamantanethiol. Following 
conjugation, no free -SH groups are observed as shown in the bottom curve, thus indicating 
successful formation of disulfide bond. (D) UV-visible absorbance and emission spectra for 
CHC-MSNs. The CHC moiety in the CHC-MSNs absorbs maximally at 405 nm and emits 
light corresponding to 450 nm, thereby acting as a FRET donor for FITC.
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(A) Schematic diagram indicating the assembly of FRET-MSNs (left), upon addition of 
FITC-β-CD to CHC-MSNs; and subsequent cleavage of disulfide bond (right), following 
treatment of FRET-MSNs with Glutathione (GSH). Inset figures show the corresponding 
change in color of the nanoparticle solution under UV lamp (365 nm). (B) Changes in blue 
(450 nm) and green (520 nm) fluorescence upon addition of increasing concentrations of 
FITC-β-CD to the CHC-MSNs dispersed in pH7.4 PBS, indicating formation of FRET-
MSNs (FRET ON). (C) Changes in blue (450 nm) and green (520 nm) fluorescence upon 
addition of increasing GSH concentrations to FRET-MSNs dispersed in pH7.4 PBS, 
indicating cleavage of disulfide bond (FRET OFF).
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(A) Scheme showing the release of DOX at different concentrations of GSH and the 
corresponding change in FRET signal as well color of FRET-MSNs. (B) Percent DOX 
released from the FRET-MSNs at different time points following treatment with increasing 
concentrations of GSH. (C) Change in FRET signal R at different time points following 
treatment of FRET-MSNs with increasing concentrations of GSH. (D) Correlation between 
percent DOX released and change in FRET signal R (plotted as 1/R) at 24 h after GSH 
treatment. (a = no GSH, b = 0.1 mM GSH, c = 1 mM GSH and d = 5 mM GSH)
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(A) Confocal microscopy images (Left panel) depicting the change in FRET signal in HeLa 
cells treated with FRET-MSNs at different time points. Right panel shows the corresponding 
change in the average fluorescence intensities, when the cells were excited with 405 nm 
light (more details see Figure S7). Scale bar is 1 µm. (B) Fluorescence microscopy images 
showing the change in the fluorescence intensity (FRET channel, 405 nm excitation, top 
panel, and the merged images with FITC channel which used 488 nm as excitation, bottom 
panel) upon varying intracellular GSH concentration of HeLa cells, prior to treatment with 
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FRET-MSNs. Cells treated with N-ethyl maleimide (NEM, 5 µM) present low levels of 
GSH, thereby FRET signal is on; whereas, the cells treated with thiotic acid (TA, 10 µM) 
have increased GSH levels and hence the FRET is turned off. The bar (top left corner) 
indicates the correlation between FRET signal R and the color of the FRET-MSNs seen in 
the top panel. Scale bar is 5 µm. (C) Quantitative comparison of the relative fluorescence 
intensities (RFI, Ex = 405 nm, Em = 450 nm), of the HeLa cells treated with TA and NEM. 
(D) Correlation between FRET signal R and cell viability, when the HeLa cells were treated 
with DOX loaded FRET-MSNs at varying GSH concentrations.
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